Efficacy evaluation of serum galectin-3 in hypertension complicated with diastolic dysfunction.

Exp Ther Med

Department of Cardiovascular Medicine, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154002, P.R. China.

Published: January 2020

AI Article Synopsis

  • The study investigated the relationship between serum galectin-3 (Gal-3) levels and diastolic dysfunction in hypertensive patients, enrolling 100 patients treated with standard medications and 80 healthy controls.
  • Results indicated that Gal-3 levels were significantly higher in patients with hypertension and diastolic dysfunction compared to controls, and levels decreased after treatment but remained elevated compared to controls.
  • Gal-3 concentration was positively correlated with the severity of cardiac function, suggesting its potential as a predictive biomarker for treatment efficacy, with a sensitivity of 73.24% based on ROC analysis.

Article Abstract

Serum galectin-3 (Gal-3) in patients with hypertension complicated with diastolic dysfunction and its predictive value for efficacy were investigated. One hundred patients with hypertension complicated with diastolic dysfunction admitted to the First Affiliated Hospital of Jiamusi University from June 2017 to December 2018 were enrolled as group A, symptomatically treated with conventional drugs. Further 80 individuals undergoing physical examination during the same period were enrolled as group B. Patients in the two groups were subjected to echocardiography to observe mitral valve early peak flow velocity (EPFV), atrial peak flow velocity (APFV), maximum flow velocity ratio of early to atrial diastole (EPFV/APFV) and peak mitral annulus velocity (E/E'). Enzyme-linked immunosorbent assay (ELISA) was used to detect serum Gal-3 concentration. According to efficacy after treatment, patients in group A were divided into the effective group (71 patients) and the invalid group (29 patients). Gal-3 concentration in group A was significantly higher than that in group B (P<0.05). After treatment, the concentration in group A was significantly lower than that before treatment (P<0.05), but significantly higher than that in group B (P<0.05). Gal-3 concentration was significantly higher in patients with cardiac function grades II, III and IV than that in patients with grade I (P<0.05). According to Spearman's test, Gal-3 concentration was positively correlated with cardiac function grading (r=0.569, P<0.001). Compared with before treatment in group A, patients after treatment had significantly higher EPFV and EPFV/APFV (P<0.05), but significantly lower APFV and E/E' (P<0.05). Before treatment, Gal-3 concentration in the effective group was significantly lower than that in the invalid group (P<0.05). According to the receiver operating characteristic (ROC) curve, the area under curve (AUC) of Gal-3 concentration for evaluating efficacy was 0.792, the sensitivity was 73.24%, and the specificity was 79.31%. In conclusion, Gal-3 may be involved in the development and progression of hypertension complicated with diastolic dysfunction. Its concentration increases with the rise of cardiac function grading but significantly decreases after treatment. Therefore, Gal-3 concentration before treatment can be used as a potential predictor of efficacy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909668PMC
http://dx.doi.org/10.3892/etm.2019.8215DOI Listing

Publication Analysis

Top Keywords

hypertension complicated
12
complicated diastolic
12
diastolic dysfunction
12
group patients
12
flow velocity
12
serum galectin-3
8
patients hypertension
8
enrolled group
8
peak flow
8
gal-3 concentration
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!